Reveal LINQ Insertable Cardiac Monitor

The Reveal LINQ™ insertable cardiac monitor (ICM) with AccuRhythm™ AI algorithms is for patients experiencing infrequent symptoms that require long-term monitoring.

View video

Overview

Accuracy matters 

As one of the world's smallest ICMs,1-3 the Reveal LINQ™ ICM works continuously to capture comprehensive and actionable data up to three years. The device features AccuRhythm™ AI algorithms, which is a groundbreaking platform that applies deep learning artificial intelligence algorithms to Reveal LINQ™ data flowing into the CareLink™ network.

† Reference the Reveal LINQ™ ICM clinician manual for usage parameters.

Product features

Powerfully small and simple

  • The Reveal LINQ™ ICM is one-third the size of a AAA battery (1.2 cc).
  • It has a minimally invasive, simplified insertion procedure.
  • The device is 1.5T and 3T MRI conditional.

‡ Reveal LINQ™ has demonstrated to pose no known hazards in a specified MRI environment with specified conditions of use. Please see the Reveal LINQ™ MRI technical manual for more details.

One-third the size of a AAA battery

Reveal LINQ™ ICM next to a AAA battery to compare size with purple and blue particles in background

AccuRhythm AI algorithms

Experience the difference of Reveal LINQ™ ICM now with AccuRhythm™ AI algorithms for AF and pause.

Reveal LINQ™ ICM,4 the most studied ICM in the market — trusted in over 1 million implants4 is now enhanced with proven AI, providing smarter, more actionable data — without compromise. Preserving over 99.9% true pause and 98.2% true AF alerts relative to Reveal LINQ™ ICM, AccuRhythm™ AI algorithms significantly improve the clinic experience.5

Reveal LINQ™ ICM with an ECG strip running through it on navy and orange conceptual background

Watch our video to learn more about AccuRhythm™ AI algorithms.


How are AccuRhythm™ AI algorithms applied?

Data workflow

The AccuRhythm™ AI platform applies deep learning AI algorithms to Reveal LINQ™ ICM data flowing into the CareLink™ network to remove false AF and Pause episodes and significantly reduce clinic review burden.5

Graphic showing data flowing from the Reveal LINQ™ ICM to a cloud representing AccuRhythm™ AI to the CareLink™ network
  1. Reveal LINQ™
  2. Data to the cloud
  3. Medtronic CareLink™ network
  4. AF and Pause
  5. AccuRhythm™ AI algorithms
  6. False events
  7. True/Indeterminate events

Reduce false alerts while maintaining sensitivity

AF and Pause generate ~90% of false alerts in the ICM space.6

The AccuRhythm™ AI algorithms can save clinicians approximately 102 hours of false alert review yearly for every 100 Reveal LINQ™ ICM patients.§,◊,5

85% cumulative reduction in Reveal LINQ™ ICM false alerts.5

  • 99.9% preserved true pause alerts5
  • 98.2% preserved true AF alerts5
Chart showing data for false Pause and AF alert reduction with the Reveal LINQ™ ICM

§ The validation study performance and time study results were projected onto 86,383 Reveal LINQ patients to calculate false alert reduction per year in 100 Reveal LINQ ICM patients.

◊ Estimated time savings was calculated based on 11.3 minutes per non-actionable ICM transmission.6

Exclusive services and solutions

Reveal LINQ™ mobile manager and ICM, Medtronic Stay Connected service, and CareLink™ service all connected via Wi-Fi icons

1. Streamline device programming and interrogation.

Reveal LINQ™ Mobile Manager
A single, app-based solution for managing:

  • Device registration, activation, and CareLink™ pre-enrollment
  • Guided workflow animations
  • Integrated patient education

2. One of the world’s smallest, most accurate
ICMs.1–3

Reveal LINQ™ ICM
The Reveal LINQ™ ICM is part of the exclusive services and solutions designed to get you back to caring for patients.

3. Direct support for patient monitor connectivity issues.

BeConnected Patient Service

Our patient telephone support service frees up clinic time by providing answers to patient ICM and monitoring questions.14,15

4. Customize alerts for clinically actionable reports.

CareLink™ network
A remote monitoring network that enables data-driven care decisions:

  • CareAlert™ notifications allow for customized reports by clinic and/or individual patient.
  • Cardiac Compass™ report provides a 90-day view of patient cardiac data.

5. FocusOn™ Monitoring and Triaging Service

Staffed with certified ECG device specialists and cardiologists, our service filters out non-actionable transmissions and alerts you to only the 20% of data that requires clinical action.16-19

Freeing up time for you to concentrate on the patients who need it most.16-19

LINQ II Focus On

Proven ICM technology

  • TruRhythm™ Detection inside Reveal LINQ™ ICM features the world's most accurate AF detection algorithm3
  • 1,000+ published clinical articles and abstracts for the Reveal™ family of ICMs4

View the ICM insertion procedure animation.

Monitoring data

Long-term monitoring for better patient outcomes.

The Reveal LINQ™ ICM continuously monitors patients for up to three years. Learn more about long-term heart monitoring for suspected AF, syncope, and cryptogenic stroke.

Benefits of continuous monitoring and automatic arrhythmia detection with ICMs

 

30 days is not enough

2 years is not enough

Superior diagnostic yield

Informed treatment decisions

 Cryptogenic stroke
(CRYSTAL-AF study)

88%

of patients who had AF would have been missed if only monitored for 30 days#,7

17.6%

of cryptogenic stroke AF diagnoses occur after monitoring with an ICM for 1 and 3 years7

8.8x

more AF detected at 36 months with ICM vs. conventional follow-upΔ,7

97%

of patients in whom AF was detected received oral anticoagulants at 12 months7

Syncope

74%

of syncope diagnoses would have been missed if using a 30-day monitor strategy#,8

20%

of syncope diagnoses occur between years 2 and 39

3.6x

more likely to reach a syncope diagnosis with ICM vs. conventional care∞,10

82%

of Reveal™ ICM guided diagnoses led to treatment11

High-risk for AF (REVEAL AF study)††

84.5%

of patients with AF would have been missed if only monitored for 30 days12

16%

of patients with ICM-detected AF would have been missed if monitoring stopped at 2 years12

4.3x

more likely to reach a diagnosis with ICM in 12 months vs. one-time, 30-day monitor13

76%

of patients with ICM-detected AF had a change in clinical management12

Watch an out-of-lab procedure

Practical guide: Reveal LINQTM in a procedure room

Download the guide to learn about best practices for safe implantation and management of Insertable Cardiac Monitors (ICMs) by nurses or other healthcare professionals in a procedure room

† Reference the Reveal LINQ™ ICM clinician manual for usage parameters.

‡ Reveal LINQ™ has demonstrated to pose no known hazards in a specified MRI environment with specified conditions of use. Please see the Reveal LINQ™ MRI technical manual for more details.

§ The validation study performance and time study results were projected onto 104,315 Reveal LINQ™ patients to calculate false alert reduction per year in 200 Reveal LINQ™ ICM patients.

◊ Estimated time savings was calculated based on 11.3 minutes per non-actionable ICM transmission.6

¶ The CRYSTAL-AF Study was a randomized, controlled study conducted on 441 patients to assess whether long-term monitoring with Reveal™ XT is more effective than conventional follow-up (control) for detecting atrial fibrillation in patients with cryptogenic stroke.

#Based on Kaplan-Meier estimates.

Δ In the CRYSTAL-AF study, the control group included 88 conventional ECGs, 20 24-hour Holters, and 1 event recorder.

∞ 2018 ESC Guidelines for Diagnosis and Management of Syncope defined conventional testing as undefined physician discretion for monitoring excluding ICM, External Loop Recorder, Tilt Test, EP Study, Recurrent 12-lead ECG, or 7-day Holter monitor.

†† The REVEAL AF Study was a prospective, single-arm, multicenter study to quantify the incidence of AF in patients at high risk for but without previously known AF using an ICM (Reveal LINQ™ or Reveal™ XT).

1. Reveal LINQ™ insertable cardiac monitor clinician manual.

2. Assert-IQ™ Model DM5000, DM5300, DM5500, insertable cardiac monitor manual. 2023.

3. ICM accuracy comparison guide. Medtronic data on file. 2021.

4. Medtronic Reveal™ ICM family data. Data on file. 2024.

5. Radtke A, Ousdigian K, Koehler J, Margetta J, Han J K. AI Enables Significant Reduction of Clinic Review Burden for Legacy ICMs. Presented HRS 2024, Boston, MA.

6. O’Shea CJ, Middeldorp ME, Hendriks JM, et al. Remote monitoring of implantable loop recorders: false-positive alert episode burden. Circ Arrhythm Electrophysiol. 2021;14(11):e009635. doi: 10.1161/CIRCEP.121.009635.

7. Sanna T, Diener H-C, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–2486. doi: 10.1056/NEJMoa1313600.

8. Rogers J, et al. Abstract 272: Sensitivity of conventional monitoring strategies to diagnose patients with pause arrhythmias relative to insertable cardiac monitors. 2020 AHA QCOR Abstract.

9. Furukawa T, Maggi R, Bertolone C, Fontana D, Brignole M. Additional diagnostic value of very prolonged observation by implantable loop recorder in patients with unexplained syncope. J Cardiovasc Electrophysiol. 2012;23(1):67–71. doi: 10.1111/j.1540-8167.2011.02133.x.

10. Brignole M, Moya A, de Lange FJ, et al. 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883–1948. doi: 10.1093/eurheartj/ehy037.

11. Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace. 2011;13(2):262–269. doi: 10.1093/europace/euq418.

12. Reiffel JA, Verma A, Kowey PR, et al. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: The REVEAL AF study. JAMA Cardiol. 2017;2(10):1120–1127. doi: 10.1001/jamacardio.2017.3180.

13. Reiffel JA, Verma A, Kowey PR, et al. Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. Am Heart J. 2020;219:128–136. doi: 10.1016/j.ahj.2019.07.016.

14. BeConnected Day to Day Service - Call Time Analysis. June 2022. Medtronic Data On File.

15. BeConnected Onboarding Pilot Results - based on 104 patients. December 2020. Medtronic Data on File.

16. Cronin et al, 2012, Heart Rhythm, vol 9, n°12.

17. Giannola et al, JMIR Cardio 2019;3(2):e9815.

18. Seiler A, et al. Clinic time required for remote and in-person management of patients with cardiac devices: Time and motion workflow evaluation. JMIR Cardio. 2021;5(2):e27720.

19. Nicolle E, et al. Clinic time required to manage remote monitoring of cardiac implantable electronic devices: impact of outsourcing initial data review and triage. EP Europace. 2021;23(Supplement_3):euab116-519.

CE mark 0123